Trading Concept
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
No Result
View All Result
Trading Concept
No Result
View All Result
Home Trading News

WHO strongly advises against convalescent plasma for treating Covid patients

by
December 7, 2021
in Trading News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

RELATED POSTS

Here are Wednesday’s biggest analyst calls: Tesla, Goldman Sachs, Penn, Amazon, McDonald’s & more

Delta offers free flight changes over July Fourth weekend ahead of possible ‘operational challenges’

Blood collection specialist Kathryn Severson holds a bag of convalescent plasma from a recovered coronavirus patient at the Central Seattle Donor Center of Bloodworks Northwest during the coronavirus disease (COVID-19) global outbreak, in Seattle, Washington, September 2, 2020.

Lindsey Wasson | Reuters

The World Health Organization on Monday issued a strong recommendation against administering convalescent plasma to treat Covid-19 patients, citing research that shows no improvement in patients who received the treatment.

In convalescent plasma therapy, blood plasma is donated by someone who has recovered from the virus and transferred into a patient battling the virus with the hope the donor’s antibodies help fight the infection.

However, the WHO’s guideline development group found that “there was no clear benefit for critical outcomes such as mortality and mechanical ventilation for patients with non-severe, severe or critical illness, and significant resource requirements in terms of cost and time for administration.”

The group said the treatment also faces practical challenges, such as finding and testing donors as well as collecting, storing and transporting the plasma.

The recommendation is based on 16 trials with more than 16,000 patients with non-severe, severe and critical Covid infections. The group said research on the treatment should proceed in randomized control trials. The new recommendation is published in the British Medical Journal.

The U.S. Food and Drug Administration in February scaled back its convalescent plasma emergency use authorization to cover only hospitalized patients early in disease progression and those hospitalized who have immune system disorders in which they cannot produce a strong antibody response.

“Plasma with low levels of antibodies has not been shown to be helpful in COVID-19,” the FDA said in its revised emergency authorization in February.

The agency issued its original, broader authorization on an emergency basis in the U.S. for all hospitalized patients in August 2020 when there were no other approved treatments for the virus. During the Trump administration, Health and Human Services Secretary Alex Azar had celebrated the use of convalescent plasma at the time as a “milestone achievement” in the efforts to fight Covid.

Since then, the FDA has authorized two Covid treatments: Gilead‘s antiviral drug remdesivir in October 2020 and Regeneron‘s antibody cocktail the following month. Pfizer‘s two-dose vaccine was authorized about a year ago.

The National Institutes of Health in August also said convalescent plasma didn’t help patients in an NIH-backed study of more than 500 adult Covid patients at the University of Pittsburgh. The trial was stopped in February due to its lack of effectiveness, the NIH said.

The New England Journal of Medicine, in a study published last month, found that convalescent plasma did not prevent disease progression in high-risk outpatients when administered one week after symptom onset. It also did not improve clinical outcomes in hospitalized patients late in the course of their illness, according to the study.

However, the study found that convalescent plasma did reduce disease progression in older, outpatient adults if administered within 72 hours of symptom onset.

Pfizer and Merck are now seeking emergency use authorization for oral antiviral drugs designed to reduce the risk of hospitalization from Covid.

ShareTweetPin

Related Posts

Here are Wednesday’s biggest analyst calls: Tesla, Goldman Sachs, Penn, Amazon, McDonald’s & more

by
June 29, 2022
0

Here are Wednesday's biggest calls on Wall Street: Barclays initiates Penn as overweight Barclays initiated several casino and gaming companies,...

Delta offers free flight changes over July Fourth weekend ahead of possible ‘operational challenges’

by
June 29, 2022
0

In this article DAL An Airbus A330-323 aircraft, operated by Delta Air Lines. Benoit Tessier | Reuters Delta Air Lines...

Watch Fed Chair Powell talk live about the economy, interest rates at ECB forum

by
June 29, 2022
0

[The stream is slated to start at 9 a.m. ET. Please refresh the page if you do not see a...

Head scratcher: Analysts still see earnings rising this year even as the U.S. teeters on a recession

by
June 29, 2022
0

Two big earnings trends as we end the first half of the year and look forward to the second half:...

Crypto hedge fund Three Arrows Capital plunges into liquidation as market crash takes toll

by
June 29, 2022
0

Billions of dollars of value have been wiped off the cryptocurrency market in the last few weeks. Companies in the...

Next Post

Toyota to build $1.29 billion EV battery plant in North Carolina, create 1,750 jobs

Cloud stocks have been crushed. Here's how Jim Cramer would invest in a potential rebound

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

email

Get the daily email about stock.

Please Enter Your Email Address:



By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

MOST VIEWED

  • Forget Tesla — this auto stock is the one to buy right now, analyst says

    0 shares
    Share 0 Tweet 0
  • WHO says Covid vaccine booster programs will prolong pandemic

    0 shares
    Share 0 Tweet 0
  • Spin or Split? AT&T Has a Big Decision to Make on Discovery Stake.

    0 shares
    Share 0 Tweet 0
  • Here’s how Carl Icahn is positioning for a possible recession in America

    0 shares
    Share 0 Tweet 0
  • Some lawmakers and their families are betting thousands of dollars on crypto

    0 shares
    Share 0 Tweet 0
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
All rights reserved by tradingconcept.net
No Result
View All Result
  • Email Whitelisting
  • Home
  • Privacy Policy

All rights reserved by www.tradingconcept.net